

Epidemiology of primary hyperparathyroidism

Peter Vestergaard
Bo Abrahamsen

Incidence

The incidence has been increasing in many countries since the seventies [1; 2]. In some countries a peak incidence was reached after which the incidence declined to the same levels as were seen before the incidence started to increase [2]. This has been interpreted as the presence of a large “pool” of hitherto undiagnosed mild or asymptomatic patients, who are then diagnosed until the “pool” is emptied and the incidence decreases to the “true” incidence [2]. In Denmark an increase has also been seen, but no peak seems to have been reached [1]. However, the most recent numbers are from 1999, where approximately 250-300 new patients were diagnosed each year [1]. Among the patients approximately 60% underwent surgical treatment, i.e. approximately 150-180 surgeries per year for primary hyperparathyroidism [1]. In 2004 a total of approximately 350 parathyroid surgeries were performed in Denmark including surgical treatment of secondary hyperparathyroidism in patients with uremia

(http://www.sst.dk/Indberetning%20og%20statistik/Sundhedsdata/Download_sundhedsstatistik/Plamateriale/LPR/DSNS.aspx).

In the US between 23% and 50% [3] of patients undergo surgery, i.e. considerably less than in Denmark, probably due to more with mild disease.

In Denmark the incidence among women has increased more than in men [1] leading to a larger percentage of patients being women over time. Also the age of patients has increased meaning that the average patient at present is likely to be a woman aged 60 years or more [1].

Age distribution

This depends on the cause. In general, the incidence and prevalence increases steeply with age. However, the heritable forms (in particular MEN1, RET and HRPT2 mutations) dominate below the age of 40-50 years. As stated above, the age of the patients has increased with time [1].

Gender distribution

In general around 75% of newly diagnosed patients are women and 25% are men. However, in the hereditary forms which are autosomally dominantly inherited a 50:50 gender distribution is seen.

Geographical distribution

The incidence varies considerably between countries. In the US an incidence of 27/100,000/year has been reported for the period 1973-1999 [2], whereas in Denmark the incidence was as low as around 4/100,000 per year for women and around 1,5/100,000/year for men between 1990 and 1999 [1]. No systematic overview of variations in incidence is available.

Single adenoma vs. hyperplasia

In general around 90% of the patients have a single adenoma, a few have adenomas of two or three glands, while around 10% have hyperplasia of all parathyroid glands [4]. Parathyroid cancer is very rare. Hyperplasia is prominent in patients with MEN1 gene mutations and HRPT2 mutations, while patients with RET protooncogene mutations may have single adenomas [5].

Severity of disease

In recent years the severity of newly diagnosed cases has been declining. Fewer patients have kidney stones [6-8], serum calcium levels have been declining [1], and the weight of pathological parathyroid tissue removed has been declining [1]. As a consequence, fewer patients undergo

surgical treatment [1].

Survival

Reports on survival after a diagnosis of hyperparathyroidism have been variable and depending on severity of the disease and surgery or not. American data from patients with mild primary hyperparathyroidism have even reported better survival in patients with primary hyperparathyroidism than in the general population [9]. However, Swedish studies in more severely affected patients with primary hyperparathyroidism have shown an increased risk of death in patients with primary hyperparathyroidism [10].

Several risk factors for mortality in patients with primary hyperparathyroidism have been reported. In a Swedish study, diabetes, uric acid, and cardiovascular disease were risk factors for mortality [11]. Higher adenoma weight also seem to be a risk factor for death [12]. Kidney stones [13; 14], absence of osteoporosis [13] and absence of muscle weakness [13] seem associated with better survival.

Patients undergoing surgery seemed to have a lower risk of death than conservatively treated patients [1; 14].

The outcome of surgery is better in recent series than in prior series [1; 15]. In recent Danish series, the risk of death following surgical treatment is the same as in the background population both early after surgery and many years after surgery [1], whereas an increased mortality is present in conservatively treated patients [1].

Bibliography

- [1] Vestergaard P, Mosekilde L. Incidens af primær hyperparatyroidisme, hyppighed af operation og mortalitet belyst ved data fra Landspatientregistret. *Ugeskr Laeger* 2004; 166: 41-45.
- [2] Wermers R, Khosla S, Atkinson E, Hodgson S, O'Fallon W, Melton, L.J., III. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. *Ann Intern Med* 1997; 126: 433-440.
- [3] Silverberg S, Shane E, Jacobs T, Siris E, Bilezikian J. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. *N Engl J Med* 1999; 341: 1249-1255.
- [4] Vestergaard P, Mollerup C, Frøkjær V, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. *BMJ* 2000; 321: 598-602.
- [5] Akerström G, Stålberg P. Surgical management of MEN-1 and -2: state of the art. *Surg Clin North Am* 2009; 89: 1047-1068.
- [6] Klugman V, Favus M, Pak C. **Nephrolithiasis in primary hyperparathyroidism.** In *The parathyroids - basic and clinical concepts*. Bilezikian J, Marcus R & Levine M (Eds.). 1994. pp. 505-517.
- [7] Silverberg SJ, Shane E, Jacobs TP, Siris ES, Gartenberg F, Seldin D et al. . Nephrolithiasis and bone involvement in primary hyperparathyroidism. *Am J Med* 1990; 89: 327-334.
- [8] Mollerup C, Vestergaard P, Frøkjær V, Mosekilde L, Christiansen P, Blichert-Toft M. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. *BMJ* 2002; 325: 807-812.
- [9] Wermers R, Khosla S, Atkinson E, Grant C, Hodgson S, O'Fallon W et al. . Survival after the diagnosis of hyperparathyroidism: a population-based study. *Am J Med* 1998; 104: 115-122.
- [10] Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism--an update [see comments]. *Eur J Clin Invest* 1998; 28: 271-276.
- [11] Bergenfels A, Bladström A, Their M, Nordenström E, Valdemarsson S, Westerdahl J. Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. *World J Surg* 2007; 31: 1393-400; discussion 1401-2.
- [12] Hedback G, Oden A, Tisell L. Parathyroid adenoma weight and the risk of death after treatment for primary hyperparathyroidism. *Surgery* 1995; 117: 134-139.
- [13] Soreide J, van Heerden J, Grant C, Yau Lo C, Schleck C, Ilstrup D. Survival after surgical treatment for primary hyperparathyroidism. *Surgery* 1997; 122: 1117-1123.
- [14] Vestergaard P, Mosekilde L. Cohort study on the effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. *BMJ* 2003; 327: 530-535.
- [15] Hedbäck G, Oden A, Tisell L. The influence of surgery on the risk of death in patients with primary hyperparathyroidism. *World J Surg* 1991; 15: 399-405; discussion 406-.